Mambalgin-1 vs Didemnin B
Head-to-head comparison of Mambalgin-1 (Mambalgin-1 from Dendroaspis polylepis venom) and Didemnin B (Didemnin B) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mambalgin-1 | Didemnin B |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Mambalgin-1 from Dendroaspis polylepis venom | Didemnin B |
| Molecular Weight | 6,300 Da | 1112.4 Da |
| Half-Life | Minutes to hours | N/A |
| Amino Acids | 57 | N/A |
| Typical Dose | 0.1-1 nmol intrathecal|10-100 nM in vitro|single-dose rodent studies | 0.05-2 mg/m2 IV in early trials |
| Route | Intrathecal | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 55 | 120 |
| Research Status | Pre-clinical | Clinical |
Mambalgin-1 Benefits
- ✓ASIC channel inhibition
- ✓non-opioid analgesia research
- ✓sensory-neuron physiology
- ✓lead optimization for pain therapeutics
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
Mambalgin-1 Dosing
Intrathecal pain-behavior studies|ASIC1a/ASIC1b electrophysiology|Acute dosing in rodents
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
Mambalgin-1 Side Effects
- ⚠Hypoactivity at high dose
- ⚠off-target ASIC blockade
- ⚠local irritation
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Research Overview
Mambalgin-1
Pre-clinical work shows mambalgin-1 can reduce pain behaviors by modulating proton-gated ion channels in peripheral and central pathways. It has become an important template for developing ASIC-targeted analgesics.
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.